Research offers explanation for ineffectiveness of checkpoint immunotherapy against bladder cancer
Can't see this email? View it online
   
  August 20, 2017  
  Bladder Cancer  
  The latest bladder cancer news from News Medical  
 Research offers explanation for ineffectiveness of checkpoint immunotherapy against bladder cancerResearch offers explanation for ineffectiveness of checkpoint immunotherapy against bladder cancer
 
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.
 
 
 Early life exposure to antibacterials could cause irreversible outcomesEarly life exposure to antibacterials could cause irreversible outcomes
 
Lawrence Livermore National Laboratory scientists have discovered that exposure to environmental levels of triclocarban (TCC), an antibacterial chemical common in personal care products like soaps and lotions as well as in the medical field, can transfer from mother to offspring and interfere with lipid metabolism.
 
   New research suggests cell immortalization as more complicated process than originally thoughtNew research suggests cell immortalization as more complicated process than originally thought
 
A mutation that helps make cells immortal is critical to the development of a tumor, but new research at the University of California, Berkeley suggests that becoming immortal is a more complicated process than originally thought.
 
 Managing Neurogenic Bladder
 
Managing Neurogenic BladderNeurogenic bladder control is a condition of loss of urinary function due to nerve, spinal cord or brain damage. A variety of circumstances can lead to neurogenic bladder, including spinal injury, neurologic disorders, or systemic disease of the body like diabetes.
 
 
 Diagnosing prostate cancer through a £225 urine test
 
Diagnosing prostate cancer through a £225 urine testThis test, which we have branded SelectMDx for Prostate Cancer, came with the acquisition of a company in the Netherlands called NovioGendix. They developed a prototype assay, so they did most of the heavy lifting in terms of discovering the two specific biomarkers that are currently in the product. These biomarkers are tuned towards the detection of what I call clinically significant prostate cancer.